A study that investigated the effects of insulin and GLP-1RAs (exenatide and dulaglutide) on BMD over a 52-week duration gathered 70 individuals with type 2 diabetes
Despite the limitations like small sample size, the recruitment limited to two stages of DKD, the assessment of only an acute effect of the drug our study found a short-term hypertensive effect of GLP-1R agonist liraglutide in diabetic kidney disease that seems to be related to impaired renal sodium excretion
FDA Drug Safety Communication: Update on FDAs ongoing evaluation of reports of suicidal thoughts or actions in patients taking certain GLP-1 receptor agonists
You still choose what to eat, portion sizes, and activity level
Carry a small, sealable sharps container
Increasing Cost Medicare spending on 10 diabetes drugs, including GLP-1s, more than quadrupled over a five-year period, and could reach $102 billion in 2026